Market News & Trends
MorphoSys & Immatics Biotechnologies Enter Strategic Alliance
MorphoSys AG and Immatics Biotechnologies GmbH recently announced a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells.…
Dauntless Pharmaceuticals & Aegis Therapeutics Announce Licensing Agreement
Dauntless Pharmaceuticals, Inc. and Aegis Therapeutics, LLC recently announced a licensing agreement providing Dauntless' access to Aegis' Intravail drug delivery technology for an undisclosed oncology…
Corium Receives US Patent for Dissolving “Drug-in-Tip” MicroCor Transdermal Patches
Corium recently announced the issuance of a patent relating the company’s unique dissolving “Drug-in-Tip” MicroCor transdermal patch, which enables the needle-free delivery of biologics, vaccines,…
Cell Culture & Upstream Processing - BioProcess International Conference Pre-Event Podcast Series
Development of a Scaleable and Productive Insect Cell Culture Based Process for Making Flublok, The First FDA Licensed Recombinant Influenza Vaccine Barry Buckland, Senior Advisor,…
Life Cycle Management Strategies More Crucial than Ever for Pharmaceutical Success
With shrinking Research and Development (R&D) pipelines and mounting costs involved in drug development, it is becoming increasingly important for pharmaceutical companies to implement suitable…
Janus Biotherapeutics Enters Collaboration With Roche
Janus Biotherapeutics recently announced it has entered into a collaboration with Roche for the development of a small molecule toll-like receptor (TLR) inhibitor with the…
Presage Biosciences Receives Strategic Investment from Takeda
Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, recently…
Enteris Biopharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' Peptide
Enteris BioPharma, Inc. congratulates Cara Therapeutics on the dosing of the first patients in a Phase II trial of an oral tablet formulation of its…
Edge Therapeutics Reports Positive Top-Line Phase I/II NEWTON Trial Results
Edge Therapeutics, Inc. recently announced that its recently completed North American Phase I/II NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage)…
Charleston Laboratories Announces Completion of Second Phase III Trial
Charleston Laboratories, Inc. recently announced completion of their second Phase III clinical study on CL-108, a novel bi-layered tablet containing 7.5 mg of hydrocodone and…
Former Unilife Employee Issues Apology & Withdraws Whistleblower Lawsuit
Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer, manufacturer and supplier of injectable drug delivery systems, recently announced that a former employee has agreed…
Brazil’s Pharmaceutical Market Value Will Approach $48 Billion
The Brazilian pharmaceutical market will expand in value from $29.4 billion in 2014 to reach approximately $47.9 billion by 2020, representing a strong Compound Annual…
VBL Announces First Patient Dosed In Pivotal Phase III Trial
VBL Therapeutics recently announced that the first patient has been dosed in the company's GLOBE Study, a pivotal Phase III trial of VB-111, an intravenously…
NanoViricides Reports Dramatic Effects of Topical Anti-Herpes Treatment Were Reproduced Once Again
NanoViricides, Inc. recently reported that the dramatic improvements in clinical symptoms associated with herpes simplex virus infection were reproduced in an animal model in a…
BioClin Therapeutics Initiates Phase II Clinical Trial for Urothelial Cell Carcinoma
BioClin Therapeutics, Inc. recently announced it has initiated a Phase II clinical study of B-701, an anti-FGFR3 antibody being investigated for the treatment of locally…
Pluristem in Key Discussions With Europe's Adaptive Pathways Group on Phase II Protocol
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, recently announced it has conducted detailed discussions with the European Adaptive Pathways Discussion Group…
Corbion & MedinCell Form Strategic Joint Venture
The joint venture, CM Biomaterials, will sell the PEG / PLA co-polymers to MedinCell partners who license the MedinCell technology (BEPO). Manufacturing of the polymers…
HERMES PHARMA Brings Easy-to-Swallow Medicines to US Market
HERMES PHARMA, Europe's largest developer and manufacturer of user-friendly solid oral dosage forms, recently announced plans to ramp up its expansion into the US market.…
Proteon Therapeutics Initiates Second Phase III Clinical Study
Proteon Therapeutics Inc. recently announced that the first patient has been treated in a second Phase III clinical study of investigational vonapanitase (formerly PRT-201), the…
Sigma-Aldrich's $17-Billion Buy-Out Seen as Boost for Lab Suppliers
By: Bill Berkrot The large premium Germany's Merck KGaA (MRCG.DE) agreed to pay in a $17-billion (10.37 billion pounds) acquisition of Sigma-Aldrich Corp (SIAL.O) shines…
